Loading
Prostate Cancer Treatment and Research / Nanoparticle-based Drug Delivery / Nanoplatforms for Cancer Theranostics · Journal article
International Journal of Nanomedicine · August 1, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of nanotechnology platforms for prostate cancer diagnosis and treatment, examining PSMA-targeted delivery, tumor microenvironment-responsive systems, and immunomodulation. The review identifies promising preclinical concepts and barriers to clinical translation—including heterogeneous PSMA expression and manufacturing challenges—but does not present a controlled trial result or quantified clinical efficacy.
Narrative review. Prostate cancer patients, particularly those with castration-resistant disease; specific clinical cohort sizes and eligibility criteria not detailed in abstract..
PSMA-negative expression occurs in 15–37% of castration-resistant prostate cancer cases, limiting PSMA-targeted nanoplatform utility Nanoparticle-based molecular imaging probes enhance detection sensitivity and specificity for diagnosis PSMA-targeted liposomes, polymeric nanoparticles, and inorganic nanocarriers enable delivery of chemotherapeutics, gene-editing tools (CRISPR/Cas9, siRNA), and immunomodulators
Long-term safety data, manufacturing feasibility, and regulatory approval status not quantified
Clinicians should note that PSMA-targeted nanoplatforms represent emerging therapeutic and diagnostic strategies still in preclinical and early translational phases. The reported heterogeneity in PSMA expression indicates that a subset of patients may not benefit from PSMA-directed approaches, and significant regulatory and manufacturing hurdles remain unresolved.
This is a narrative review synthesizing preclinical and early-stage work on nanoplatform design; it raises therapeutic and diagnostic opportunities but does not report a primary clinical trial result, efficacy comparison, or outcome data.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should note that PSMA-targeted nanoplatforms represent emerging therapeutic and diagnostic strategies still in preclinical and early translational phases. The reported heterogeneity in PSMA expression indicates that a subset of patients may not benefit from PSMA-directed approaches, and significant regulatory and manufacturing hurdles remain unresolved.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract: The field of nanotechnology has demonstrated considerable potential in the diagnosis and treatment of prostate cancer, particularly through the use of prostate-specific membrane antigen (PSMA)-targeted platforms and tumor microenvironment (TME)-responsive systems. In the context of diagnosis, nanoparticle-based molecular imaging probes have been shown to enhance detection sensitivity and specificity. These probes include superparamagnetic iron oxide, which is utilized in magnetic resonance imaging, and near-infrared fluorescent nanomicelles. Additionally, nanostructured liquid biopsy systems have demonstrated the capability to capture circulating tumor cells, exosomes, and circulating tumor DNA with high sensitivity, facilitating non-invasive genotyping and treatment monitoring. In the field of therapeutics, PSMA-targeted liposomes, polymeric nanoparticles, and inorganic nanocarriers have demonstrated efficacy in enhancing the delivery of chemotherapeutics, gene-editing tools (eg, CRISPR/Cas9, siRNA), and immunomodulators. These delivery mechanisms are equipped with TME-responsive release mechanisms (eg, pH, enzyme, redox) that enable the spatiotemporal control of drug release. Nanotechnology offers multi-level strategies to overcome multidrug resistance in castration-resistant prostate cancer, including PROTAC-mediated protein degradation, ferroptosis induction, and synergistic chemo-immunotherapy. Multifunctional theranostic nanoplatforms integrating imaging and therapy enable real-time efficacy assessment and personalized treatment adaptation. Emerging green synthesis approaches that utilize agricultural byproducts and bio-inspired platforms (eg, cell membrane-coated nanoparticles) present sustainable and biocompatible alternatives. Concurrently, artificial intelligence (AI) holds the potential to expedite the design of nanocarriers. Despite the advancement of several nanomedicines to clinical trials, significant translational barriers persist. These include heterogeneous PSMA expression (15– 37% of castration-resistant prostate cancer cases are PSMA-negative), suboptimal enhanced permeability and retention effect in humans, long-term safety concerns, manufacturing hurdles, and regulatory gaps. This narrative review methodically examines the applications of nanotechnology in prostate cancer. It critically analyzes the clinical translation challenges encountered during clinical trials and discusses future directions, including smart responsive systems, multimodal immunotherapy, and AI-assisted nanomedicine design. Keywords: nanotechnology, prostate cancer, targeted delivery, integrated diagnosis and treatment, clinical translation
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.